More recently, they have become widely known for their effectiveness in promoting weight loss
The absence of a Chief Pharmacist in Queensland during COVID-19 saw delays in implementing vital initiatives to support continuing medicine supply, such as digital image prescriptions and electronic prescriptions, Mr MacDonald said
Over 18 months, about nine out of every 10,000 people in the GLP-1 group were diagnosed with ischemic optic neuropathy, compared with about six out of 10,000 in the GLT2 inhibitor group and about four out of 10,000 in the DPP4 inhibitor group
What if I miss an injection
The SUSTAIN and STEP trial series for semaglutide demonstrated 1015% body weight reduction over 68 weeks in the STEP 1 trial (Wilding et al., 2021, NEJM: The SURMOUNT-1 trial for tirzepatide demonstrated up to 20.9% weight reduction at the highest dose (Jastreboff et al., 2022, NEJM: Retatrutide Phase II data (Jastreboff et al., 2023, NEJM) showed up to 24.2% weight loss, the highest reported for any pharmacological intervention in a randomised trial at the time of publication
Purpose-built for physicians GLP-1s hold promise in MS, but more rigorous examination is required Key takeaways: There is limited evidence of GLP-1 receptor agonist safety and efficacy in MS